{
  "id": 21301542,
  "title": "CeriBell: 3 Key Takeaways for Long-Term Investors",
  "url": "https://urgent.news/2026/11/22/ceribell-3-key-takeaways-for-long-term-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T22:30:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/takeaways/2026/11/22/ceribell-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "CeriBell (CBLL) reported its third-quarter 2026 earnings on November 3, 2026, announcing full-year revenue guidance of $115 million to $117 million. The company's gross margins stood at 90%, and its hardware capabilities are expanding, providing operating leverage as it enters untapped market opportunities such as delirium monitoring. Key takeaways for long-term investors include CeriBell's introduction of a delirium monitoring tool as a fee-free software update, which will drive revenue through increased usage of single-use headbands, and the launch of Omni, a hardware platform that merges quick bedside EEG brain monitoring with traditional multi-day continuous recording. The company's high gross margins and strong balance sheet provide confidence in achieving self-funded profitability.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}